Evidence mapPaperPMID 38523633Full record

ReviewFrontiers in pharmacology2024

Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition.

Xiao-Jun Li, Ping Suo, Yan-Ni Wang, Liang Zou, Xiao-Li Nie, Ying-Yong Zhao, Hua Miao

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Microbiota-gut-kidney axis in health and renal disease.International journal of biological sciences · 2026
    Review
  9. Article
  10. Uncovering the mechanistic basis ofPharmaceutical biology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Short-Term Intake ofAntioxidants (Basel, Switzerland) · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xiao-Jun Li *School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Ping Suo *School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yan-Ni WangSchool of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Liang ZouSchool of Food and Bioengineering, Chengdu University, Chengdu, Sichuan, China.
Xiao-Li NieDepartment of Nephrology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China.
Ying-Yong ZhaoSchool of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Hua MiaoSchool of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Zhejiang Chinese Medical University · CNChengdu University · CNTCM-Intigrated Cancer Center of Southern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arachidonic acid (AA) is a main component of cell membrane lipids. AA is mainly metabolized by three enzymes: cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP450). Esterified AA is hydrolysed by phospholipase A

Indexed as

acute kidney injuryarachidonic acidchronic kidney diseaseinflammationoxidative stressrenal cell carcinoma

Identifiers

PMID38523633
PMCPMC10957658
OpenAlexW4392626626

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.